Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	December 14, 2023
Length of Meeting:	2 hours and 14 minutes
Location of Meeting:	DMAS Board Room 102

Members Present:
John Morgan, MD, Chief Clinical Innovation Officer, Chair
Rachel Cain, PharmD
Denise Lowe, PharmD
Elizabeth Gaughan, MD
Matthew Estes, PharmD
Melissa Chouinard, MD
Michele Thomas, PharmD
Wendy Nash, PharmD
Jack Weisskohl, NP

Members Not Present:

Seth Brant, MD
Kathryn Reid, PhD
Kristi Fowler, RPh
Denese Gomes, NP

DMAS Attendees:
MaryAnn McNeil, RPh, Pharmacy Manager
JoeMichael Fusco, PharmD, Common Core Formulary Pharmacist
Kara Radenmeyer, PharmD, PhD

Contractors:
Debbie Moody, RPh, Director, Clinical Account Services, Magellan Health Services
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Health Services
David D'Amico, PharmD, Pharmacist Account Executive, Magellan Health Services

Visitors:
Marc Katabird

Kristie Bryerton
Katherine Klem
Brian Trentler, PharmD, Pharmacy Director, United Healthcare
Scott Burns
Rob Berringer, PharmD, Director, Health Plan Pharmacy Services, Molina Healthcare of Virginia
Carrie Martle
Heidi Dix

Call to Order and Introductions

Dr. John Morgan welcomed and thanked everyone for attending the DUR meeting.

Dr. Morgan called the meeting to order at 1:06 pm.

Dr. Rachel Cain introduced one new DUR Board Member:

- Jack Weisskohl, NP

Minutes – September 14, 2023

Dr. Michele Thomas motioned to approve the September 14, 2023 meeting minutes as submitted. Dr. Chouinard seconded the motion.

By-Laws Review

Dr. Cain discussed the updates to the DUR By-Laws. Changes were reviewed and voted on. Approved by Dr. Thomas, seconded by Dr, Chouinard. All members were in favor.

Review Members and Nominations

Dr. Cain announced there is vacancy on the Board for a physician. She requested the Board members email their individual affiliations listed in the Virginia Code to her. Also, she asked for their thoughts on disciplines for the new physician candidate, a new chair and vice chair.

New Drugs

The DUR Board reviewed Akeega™ (niraparib and abiraterone), Ojjaara™ (momelotinib), and Vanflyta® (quizartinib). The Impact Report and the report for the utilization of these new drugs for FFS and MCOs were reviewed.

The DUR Board discussed the service authorization (SA) for Ojjaara™ which is found on the Oral Oncology SA form. Dr. Gaughan requested removing the

double negative in question 6. She recommended changing the wording to “The member has not experienced unacceptable toxicity from the drug.” Dr. Thomas made the motion. Seconded by Dr. Chouinard. This language was approved for all fax forms where appropriate.

The DUR Board discussed the service authorization criteria for Vanflyta®. The Board recommended removing the REMS program requirement from the form since the claims will not pay without it. Question 5 is to be reworded to “Does the member continue to experience clinical benefit from the requested treatment?” Motion Dr. Morgan, second Dr. Thomas. This language was approved for all fax forms where appropriate.

SA Form Revisions

The DUR Board discussed changing questions 5 and 6 on the Oral Oncology – Prostate SA form to the same verbiage as question 5 and 6 on the Oral Oncology SA form. Dr. Gaughan recommended adding Urologists to the specialties required in question 1 for the 6 hormonal drugs that urologists use in practice. Seconded by Dr. Morgan.

Jack Weisskohl recommended adding an additional check box and fill in space under all SA forms for gender to cover “Other” to include members who do not identify as male or female. Seconded by Dr. Thomas.

Dr. Michelle Thomas offered to contact a specialist for their expertise on the Cuvrior SA form on question 5. This SA form was tabled pending that discussion. Dr. Morgan agreed on the collaboration. Motion by Dr. Thomas and seconded by Dr. Chouinard.

The DUR Board discussed the updates to the SA criteria for Joenja. Dr. Chouinard recommended combining question 3 and 4 to streamline the diagnosis related questions. Motioned by Dr. Morgan, seconded by Dr. Estes.

Follow up on Youngest Children on Antipsychotics, Antidepressants and/or Mood Stabilizers

The DUR Board reviewed the utilization of antidepressants, antipsychotics, and mood stabilizers for children 2 and younger at their September meeting. Dr. Cain has sent the lists of members to the individual MCO pharmacy directors for follow up. Dr. Nash requested a full medication list and diagnosis for the one member who was prescribed risperidone for follow up at the next meeting.

Hepatitis C Compliance

Hepatitis C prescribing and compliance data were reviewed by the DUR Board. Dr. Morgan recommended re examining the data while looking at the 30% deemed not compliant and looking at those members eligibility. Dr. Nash requested more information on the compliance of members on the non-preferred agents. Dr. Thomas asked if the MCOs provide any outreach for Hepatitis C follow up? Dr. Lowe replied that specialty pharmacies do outreach but does not know if the MCOs provide outreach. Dr. Lowe asked if any MCOs differ in compliance? These questions will be followed up on at the next DUR meeting.

MRx Pipeline and DUR Quarterly Newsletter- The October 2023 MRx Pipeline Report and the September 2023 DUR Quarterly Newsletter were available on the DUR Webportal for review.

Topics for Discussion

Concurrent Use of Opioids and Benzodiazepines – The DUR Board reviewed Concurrent Use of Opioids and Benzodiazepines reports for FFS and MCOs. Dr. Chouinard requested ICD10 codes for the eight FFS members to try and determine the reason for concomitant use at the next DUR meeting in March.

Concurrent Use of Opioids and Antipsychotics – The DUR Board reviewed Concurrent Use of Opioids and Antipsychotics reports for FFS and MCOs. The ICD10 codes for the FFS members will be reviewed to try and determine the reason for concomitant use at the March DUR meeting.

Overlaps in Opioids, Benzodiazepines, and Antipsychotics – The DUR Board reviewed reports with both FFS and MCO data during the time frame of October 1, 2022 through September 30, 2023 and looked at members with concurrent use of opioids, benzodiazepines, and antipsychotics. The DUR Board expressed an interest in bringing back the steps that are taken by DMAS and Magellan to make sure the criteria, indications, and call center approval/denial flow process are appropriate and up-to-date for antipsychotic medications in children and follow up for individual members under the age of 2.

Reports

ProDUR

The DUR Board reviewed the ProDUR reports. Magellan is working on having a new version of the ProDUR Top Encounters by Problem Type Report to look at only the severity level 1 ProDUR edits. Dr. Nash requested more information

from First DataBank on how things like “single live births for Adderal” and “hypoxia for metformin” appear in the ProDUR report.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports.

Dr. Cain has reached out to CMS for clarification on required RetroDUR activity. CMS responded that monthly lettering is not required but some type of information should be sent out to prescribers to make sure they are doing their due diligence and to bring things to their attention that we find. With that, instead of sending out monthly RetroDUR letters, DMAS will be altering this slightly and maybe sending out more informational letters instead of letters requesting the responses. Dr. Chouinard asked about sending letters directly to the member. Dr. Cain responded that this is a goal however given the transient population and lack of funding for these letters they are not sent to the member at this time.

II. RetroDUR Criteria Estimates

The Criteria Exception Estimates Reports were provided in the binder for review. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for Fee-For-Service (FFS) and each individual Managed Care Organization (MCO) plan. The Board recommended lettering on Criteria IDs 7777 and 7848 for asthmatics based on any new guidelines.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. The Top 25 Drugs Ranked by Claim Count and the Top 25 Drugs Ranked by Payment Amount pharmacy claims were reviewed and examined by at the total drug, brand and generic level. All versions across FFS and MCOs to be included in future meetings.

Physician Administered Drug (PAD) Program Announcement

Dr. Cain introduced the PAD program to the DUR Board and asked for thoughts on the program and feedback to potential effects of the program. Also DMAS is interested in how this program may impact their practices. Dr. Gaughan asked if drugs will still be available on the medical side. Dr. Cain responded that some drugs will remain on the medical side. Dr. Cain encouraged the Board to have input in this program.

Next DUR Meeting

March 14, 2024.

Dr. Morgan motioned to adjourn the meeting. Dr. Thomas seconded the motion. Meeting adjourned at 3:20 pm.